Electroporation and Nucleofector^® Technology

The Nucleofector^® Technology, introduced to the market by legacy Amaxa in 2001, uses a specific combination of optimized electrical parameters and cell type-specific solutions, which enables transfer of a molecule directly into the cell’s nucleus. Thus, Nucleofection^® is independent from cell proliferation and allows the transfection of non-dividing primary cells (e.g. resting T cells or neurons). 
Three specialized components are key to the efficient transfection of primary cells or cell lines using a variety of substrates:

1.  A Nucleofector^® System that comprises unique electrical parameters pre-programmed for each optimized cell type, to deliver the substrate directly into the cell nucleus and the cytoplasm. The different platforms we offer provide different specifications for various applications. Find further information below.
2. Nucleofector^® Kits, containing dedicated Nucleofector^® Solutions and Supplements. These act as a protective environment for high transfection efficiency and cell viability, while maintaining physiologically relevant cellular conditions. Specified Nucleofection^® vessels, pipettes, and a fluorescent positive control vector (pmaxGFPTM Control Vector) are also provided.
3. Optimized protocols offering comprehensive guidance for optimal Nucleofection^® Conditions along with tips for cell sourcing, passage, growth conditions and media, and post-transfection culture. You can also learn more about how to optimize Nucleofection^® Conditions here. 

Since launching the Nucleofector^® Technology by legacy Amaxa, we have introduced several innovations around those three components to expand its application to further cell types, lower and higher cell numbers or different throughputs.

---

 

Nucleofector^® Technology – Key benefits

• Transfection of a wide range of substrates, including DNA, mRNA, RNPs, miRNA, siRNA, peptides or proteins
• Higher transfection efficiency than other non-viral transfection methods (including traditional electroporation)
• High transfection efficiencies of up to 90% for plasmid DNA and 99% for oligonucleotides, like siRNA Excellent preservation of the physiological status and viability of transfected cells
• Analysis of transfection results shortly after transfection possible Easy-to-use technology, with over 750 cell-type specific protocols that have led to direct transfection success
• Transfection of hard-to-transfect cells, including primary cells, stem cells, neurons and cell lines, as well as cells in adherence

Additionally, using Nucleofector^® Technology can bring various practical benefits to your research, including:

• Reliance on a proven, reliable and innovative technology, that has featured in more than 21,500 peer-reviewed publications worldwide
• Reduced risk of cross-contamination using the disposable sterile Nucleocuvette^® Vessels
• Excellent technical and applicative support from a highly-skilled, specialist scientific support team
• Easy expansion of your research due to the flexible scaling capabilities of the different Nucleofector^® Platforms, including low-, medium- and high-throughput transfection and easy transfer of conditions between different platforms (find further information below)
   

These benefits can facilitate numerous applications, such as therapeutic gene knock-down via RNAi, genome editing via CRISPR, the generation and transfection of induced pluripotent stem cells or generation of CAR-T cells, among many others. It is therefore not surprising that Nucleofector^® Technology is used in many different lines of research, including functional and structural genomics, drug discovery, and gene and cell therapy.